I n 2009 I explored the transition from the Risk Minimization Action Plan (RiskMAP) program to the Risk Evaluation and Mitigation Strategy (REMS) programs. So it is only fitting in the shadow of health care reform to take a look back and see what has happened related to the REMS program over the past year.
The REMS program was created with an amendment to the Food and Drug Administration (FDA) Act in 2007 and provided the legal framework for the development of a risk management program that included all New Drug Applications (NDA) and Biologic License Applications (BLA) and all previously approved drugs. This amendment allows the FDA to implement a REMS program if new safety concerns emerge during the drug or biological approval process or after a drug or biological agent is approved. It also allows the FDA to impose civil monetary penalties for violations of the REMS provision and/or the ability to declare a drug or biological product as misbranded and take appropriate legal action for this type of infraction. [1] [2] [3] [4] [5] [6] The elements of the REMS required for a particular pharmaceutical product are dependent on its associated risks. 1, 3 The strategies used within the REMS are special labeling requirements, medication guides, communication plan, postapproval studies, and/or restricted distribution systems. 1, 3 Since implementation of the REMS program, approximately 225 branded products have been required to adopt at least one of these strategies. 7, 8 The most commonly required REMS is the medication guide. Medication guides are paper handouts that are required to be dispensed with the prescription medication. 8 These medication guides are intended to help patients avoid serious adverse events that might be associated with specific agents and drug/biological classes.
This system is no longer limited to only those drugs presented to the FDA in the form of an NDA or BLA. A REMS program can be applied to any marketed drug or biological agent if safety concerns are identified after the drug has been approved. Examples of previous approved drugs and biologic agents that now have a required REMS program within the past year are didanosine (medication guide), darbepoetin alfa (medication guide, communication plan, elements to ensure safe use, and implementation system), epoetin alfa (medication guide, communication plan, elements to ensure safe use, and implementation system), longacting inhaled beta-agonists (medication guide, communication plan), morphine sulfate oral solution (medication guide), and quetiapine (medication guide) (see Table 1 ). [7] [8] [9] [10] The FDA is also currently reviewing public and stakeholder comments on the development of REMS for other opioid drug products. 11, 12 It is still too early to tell if this type of safety-focused program, especially the use of the medication guide, has improved patient outcomes and minimized patient harm. Despite this lack of outcome data, it is still a valuable program and deserves our support. It is essential that we make sure that patient access is not negatively impact by these programs and good patient care is provided for those patients who do need these important, but more risky, medications.
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